Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study

Table 4 Multivariate analysis for CIR, RFS, and OS in patients with non-DTA genes after introduction of MFC for tandem assessment

Variables	n	CIR		RFS		OS
Variables	n	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Tandem assessment					< 0.001		0.048
F-/M-	93	1.00[Reference]		1.00[Reference]		1.00[Reference]
F-/M+	43	4.51(1.69–12.07)	0.003	2.85(1.39–6.30)	0.005	3.51(1.43–8.60)	0.006
F+/M-	6	12.46(3.22–48.21)	< 0.001	7.19(1.84–28.02)	0.004	3.02(0.34–26.80)	0.321
F+/M+	8	22.44(7.31–68.91)	< 0.001	9.97(3.52–28.22)	< 0.001	3.06(0.78-12.00)	0.108
Remission status at time of HSCT					0.169		0.358
CR1	102	1.00[Reference]		1.00[Reference]		1.00[Reference]
≥CR2	26	1.95(0.72–5.30)	0.190	1.94(0.82–4.59)	0.132	1.17(0.36–3.79)	0.795
No CR	22	1.14(0.47–2.75)	0.780	1.86(0.82–4.21)	0.135	2.01(0.77–5.25)	0.152
DRI-R
Low/Intermediate	92	1.00[Reference]		1.00[Reference]		1.00[Reference]
High/Very high	58	4.76(1.74–12.99)	0.002	5.32(2.26–12.55)	< 0.001	4.11(1.45–11.66)	0.008

Abbreviations CIR, cumulative incidence of relapse; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; F+/M+, MFC MRD-positive and non-DTA MRD-positive; F-/M+, MFC MRD-negative and non-DTA MRD-positive; F+/M-, MFC MRD-positive and non-DTA MRD-negative; F-/M-, MFC MRD-negative and non-DTA MRD-negative; CR, complete remission; CR1, first complete remission; CR2, second complete remission; DRI-R, refined disease risk index

ISSN: 1479-5876